Bio-Techne Corp

Research Bio-Techne Corp (TECH) on Bullrun: valuation model: 57.8% overvalued, market cap USD 11.10B, P/E 101.8, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTECH
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal57.8% overvalued
• Market capUSD 11.10B
• P/E101.8
• Dividend yield0.5%
• Financial periodFY2025
• RevenueUSD 1.22B
• Revenue growth5.2%
• Net incomeUSD 73.40M
• Free cash flowUSD 256.55M
• Gross margin64.8%

Valuation Snapshot

Bullrun's latest valuation model marks Bio-Techne Corp as 57.8% overvalued; latest market cap is USD 11.10B; P/E is 101.8; dividend yield is 0.5%.

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.

Frequently asked questions

Is Bio-Techne Corp overvalued or undervalued?

Bullrun's valuation model currently marks Bio-Techne Corp as 57.8% overvalued.

What is Bio-Techne Corp's market cap?

Bio-Techne Corp's market capitalization is USD 11.10B.

What is Bio-Techne Corp's P/E ratio?

Bio-Techne Corp's price-to-earnings (P/E) ratio is 101.8.

Does Bio-Techne Corp pay a dividend?

Bio-Techne Corp has a dividend yield of 0.5%.

What does Bio-Techne Corp do?

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.